Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Revlimid

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Revlimid was produced by Celgene.

Janssen scores another expansion for new Darzalex combination in the US

Janssen scores another expansion for new Darzalex combination in the US

It also has an approval for another combination regimen made up of Darzalex, Celgene’s Revlimid (lenalidomide) and dexamethasone, for the treatment of newly diagnosed multiple myeloma patients who are ineligible

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

Bristol-Myers Squibb’s revenues rise on Celgene acquisition BMS’ biggest seller was its multiple myeloma therapy Revlimid (lenalidomide), which it added to its portfolio following the Celgene acquisition.

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa The anti-CD38 antibody is an option for patients who have been treated with at least two prior therapies, including BMS’ Revlimid (lenalidomide) and a proteasome inhibitor such as Takeda’s

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma The 750-patrient ELOQUENT-1 trial showed that adding Empliciti (elotuzumab) to background treatment with BMS/Celgene’s Revlimid (lenalidomide) and dexamethasone didn’t extend the time patients with newly-diagnosed ... That said, “Empliciti,

FDA approves Sanofi’s key cancer drug Sarclisa for myeloma

FDA approves Sanofi’s key cancer drug Sarclisa for myeloma Sarclisa will now be available for patients with relapsed or refractor multiple myeloma who have received at least two prior therapies, including Celgene’s Revlimid (lenalidomide) and a proteasome inhibitor.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics